CLINICAL_TRIALS
trial_result
· 2017-08-22
Clinical Trial Update: Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009) [Phase 3]
Summary
Phase 3 trial update comparing immunogenicity and tolerability of V503 to GARDASIL; study completed with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2017-08-22